IP Library Granted Patent US 10,434,096
Granted Patent B2
US 10,434,096 · App. 16/151,959 · Granted Oct 8, 2019

Tyrosine kinase inhibitors

Inventors: Sacha Holland (San Franciso, CA); Rajinder Singh (Belmont, CA); Somasekhar Bhamidipati (Foster City, CA); Pingyu Ding (Foster City, CA); Rao Kolluri (Foster City, CA); Ihab Darwish (San Carlos, CA); Esteban Masuda (Menlo Park, CA); Jiaxin Yu (San Carlos, CA)
Assignee: RIGEL PHARMACEUTICALS, INC.
A61K31/4545A61K31/519C07D471/04C07D519/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,434,096
App. No.
16/151,959
Granted
Oct 8, 2019
Kind
B2
Abstract

Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, Y and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellular TAM receptor, and can be used to treat disease mediated by or involving the TAM receptor family.

Claims (7)

1. A compound having the structure formula

or a pharmaceutically acceptable salt, or N-oxide thereof, or a solvate or hydrate thereof.

2. A pharmaceutical composition comprising a pharmaceutically acceptable diluent, carrier, or excipient and a compound according to claim 1 .

3. A method of inhibiting a cellular TAM receptor, the method comprising contacting a cell comprising a TAM receptor with a compound according to claim 1 , or a composition of claim 2 .

4. The method of claim 3 , wherein the TAM receptor is a Tyro receptor, an Axl receptor, or a Mer receptor.

5. A method for treating a disease or condition mediated by or involving the TAM receptor family in a subject in need thereof, comprising administering an effective TAM receptor inhibiting amount of a compound of claim 1 , or a composition of claim 2 , wherein the disease or condition is a hematological neoplasm.

6. The method of claim 5 , wherein the hematological neoplasms is acute myeloid leukemia AML.

Assignments (3)
SECURITY INTEREST Recorded May 8, 2026
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 075576/0880 →
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2018
From: YU, JIAXIN; BHAMIDIPATI, SOMASEKHAR; HOLLAND, SACHA; SINGH, RAJINDER; KOLLURI, RAO; DARWISH, IHAB; MASUDA, ESTEBAN; DING, PINGYU
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 047292/0814 →
Continuity (3)
Continuation 15645775 · Jul 10, 2017
Provisional Application 62360297 · Jul 8, 2016
Related Publication 20190099411A1 · Apr 4, 2019